Gusacitinib (ASN-002)

Catalog No.S0871

For research use only.

Gusacitinib (ASN-002) is a novel and potent dual inhibitor of spleen tyrosine kinase (SYK) and Janus kinases (JAK) with IC50 values of 5-46 nM in biochemical assays.

Gusacitinib (ASN-002) Chemical Structure

CAS No. 1425381-60-7

Purity & Quality Control

Choose Selective Syk Inhibitors

Other Syk Products

Biological Activity

Description Gusacitinib (ASN-002) is a novel and potent dual inhibitor of spleen tyrosine kinase (SYK) and Janus kinases (JAK) with IC50 values of 5-46 nM in biochemical assays.
Targets
SYK [1]
()
JAK [1]
()

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 92 mg/mL
(199.76 mM)
Water Insoluble
Ethanol Insoluble

Chemical Information

Molecular Weight 460.53
Formula

C24H28N8O2

CAS No. 1425381-60-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CN(CCC1CC#N)C2=NC3=C(C(=O)NN=C3)C(=N2)NC4=CC=C(C=C4)N5CCC(CC5)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04416516 Recruiting Biological: ASN-002 Basal Cell Carcinoma|Basal Cell Nevus Syndrome Ascend Biopharmaceuticals Ltd July 16 2020 Phase 2
NCT03641573 Completed Drug: [14C] ASN002 Healthy Volunteer Asana BioSciences October 11 2018 Phase 1
NCT03654755 Terminated Drug: ASN002 Atopic Dermatitis Asana BioSciences September 29 2018 Phase 2
NCT03208296 Suspended Biological: ASN-002 Basal Cell Carcinoma in Basal Cell Nevus Syndrome Ascend Biopharmaceuticals Ltd December 1 2017 Phase 1|Phase 2
NCT03139981 Completed Drug: ASN002|Drug: Placebo Oral Tablet Dermatitis Atopic|Dermatitis Eczema|Dermatitis Eczematous Asana BioSciences April 12 2017 Phase 1
NCT02853643 Completed Drug: ASN002 Healthy Volunteers Asana BioSciences July 2016 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Gusacitinib (ASN-002) | Gusacitinib (ASN-002) supplier | purchase Gusacitinib (ASN-002) | Gusacitinib (ASN-002) cost | Gusacitinib (ASN-002) manufacturer | order Gusacitinib (ASN-002) | Gusacitinib (ASN-002) distributor